%PDF-1.3
%
3 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T0WI2P0T5T R
Ɩf
!\!Y\ !p
o
endstream
endobj
6 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T0WI2P0T5T R
Ɩf
!\!Y\ !p
o
endstream
endobj
4 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T0WI2P0T5T R
Ɩf
!\!Y\ !p
o
endstream
endobj
8 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T0WI2P0T5T R
Ɩf
!\!Y\ !p
o
endstream
endobj
1 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T0WI2P0T5T R
Ɩf
!\!Y\ !p
o
endstream
endobj
9 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T0WI2P0T5T R
Ɩf
!\!Y\ !p
o
endstream
endobj
5 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T0WI2P0T5T R
Ɩf
!\!Y\ !p
o
endstream
endobj
7 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T0WI2P0T5T R
Ɩf
!\!Y\ !p
o
endstream
endobj
11 0 obj
<>stream
Arbortext Advanced Print Publisher 9.0.114/W
2021-07-07T08:41:31-07:00
2021-07-06T15:49:13+05:30
application/pdf
LRB-2020-0126-ver9-Rockson_3P 1..8
Acrobat Distiller 8.1.0 (Windows); modified using iText 4.2.0 by 1T3XT
uuid:826ab245-6aba-4601-9c44-c34367748244
uuid:68d1e63c-393f-4d75-b67e-48ea57148a35
endstream
endobj
12 0 obj
<>stream
x+ |
endstream
endobj
13 0 obj
<>stream
xS**T0T0 Bi y8#
endstream
endobj
14 0 obj
<>stream
x+ |
endstream
endobj
15 0 obj
<>stream
xS**T0T0 Bi y\'
endstream
endobj
16 0 obj
<>stream
x+ |
endstream
endobj
17 0 obj
<>stream
xS**T0T0 Bi yn)
endstream
endobj
18 0 obj
<>stream
x+ |
endstream
endobj
19 0 obj
<>stream
xS**T0T0 Bi yJ%
endstream
endobj
20 0 obj
<>stream
x+ |
endstream
endobj
21 0 obj
<>stream
xS**T0T0 Bi yS&
endstream
endobj
22 0 obj
<>stream
x+ |
endstream
endobj
23 0 obj
<>stream
xS**T0T0 Bi yw*
endstream
endobj
24 0 obj
<>stream
x+ |
endstream
endobj
25 0 obj
<>stream
xS**T0T0 Bi yA$
endstream
endobj
26 0 obj
<>stream
x+ |
endstream
endobj
27 0 obj
<>stream
xS**T0T0 Bi ye(
endstream
endobj
29 0 obj
<>stream
/GS1 gs
BT
/F4 1 Tf
9.843 0 0 9.843 72 725.1588 Tm
0 0 0 rg
0 Tc
0 Tw
[(With)-502.3(lymphedema,)-504.4(the)-499.9(malformation)-507.9(or)-503.3(destruction)-504.2(of)]TJ
-1.0137 -1.1174 TD
[(lymphatic)-584.1(pathways)-587.9(leads)-583.7(to)-578.3(excessive)-590.3(buildup)-583.9(of)-578.1(uid)]TJ
0 -1.1116 TD
[(and)-292.4(protein)-297.1(in)-290.3(interstitial)-298.4(spaces,)-295.4(and)-298.2(can)-293.6(lead)-294.8(to)-290.3(disguring)]TJ
T*
[(swelling,)-342.8(pain,)-337.4(restricted)-342.9(range)-336.1(of)-336.2(motion,)-339.8(hardening)-340.6(of)-336.2(the)]TJ
T*
[(skin)-246.2(\(brosis\),)-254.7(and)-246.4(recurring)-248.4(infections.)]TJ
7.3823 0 0 6.5614 217.9842 685.7006 Tm
(1215)Tj
9.843 0 0 9.843 238.9039 681.3352 Tm
[(Management)-254.1(of)]TJ
-17.9703 -1.1174 TD
[(this)-188.8(chronic)-194.4(condition)-190(requires)-195.3(a)-192.3(lifetime)-191.4(of)-192.2(careful)-189.8(and)-194.5(some-)]TJ
0 -1.1116 TD
[(times)-434.2(burdensome)-429.1(self-care)-440.6(to)-428.5(avoid)-427.3(these)-434(adverse)-437.2(conse-)]TJ
T*
[(quences.)-279.4(Specic)-276(treatment)-279.9(for)-273.9(lymphedema)-276.3(depends)-274.8(on)-272.9(the)]TJ
0 -1.1174 TD
[(severity)-333.7(of)-330.5(the)-332.9(condition,)-331.7(which)-336(may)-328.2(progress)-332.1(if)-330.6(treatments)]TJ
0 -1.1116 TD
[(are)-552.8(not)-556.4(adhered)-552.6(to.)-552.9(Complex)-552.7(decongestive)-559.4(therapy)-551.5(with)]TJ
T*
[(manual)-499.9(lymph)-502.2(drainage)-502(\()-81.7(MLD\))-502.7(and)-499.8(frequent)-500.8(wearing)-500.6(of)]TJ
0 -1.1174 TD
[(compression)-320.7(garments)-317.5(are)-310.9(consid)-7.7(ered)-312(current)-315.4(treatment)-320.3(and)]TJ
0 -1.1116 TD
[(are)-322.4(used)-322.2(to)-319.1(manage)-322.4(symptoms.)]TJ
7.3823 0 0 6.5614 186.1795 597.9967 Tm
(1619)Tj
9.843 0 0 9.843 207.8362 593.6313 Tm
[(Meticulous)-319.7(skin)-321.1(care)-324.6(is)]TJ
-14.814 -1.1116 TD
[(always)-389.9(required,)-394.8(and)-390.4(jewelry,)-389(tight)-391.8(clothing,)-388.2(venipuncture,)]TJ
T*
[(an)19.7(d)-214.2(o)0(t)20.7(h)0(e)19.7(r)-214.2(in)20.7(su)15.3(lt)20.6(s)-214(t)0(o)-203.9(t)0(h)20.7(e)-209.6(af)14(fe)19.7(ct)19.5(ed)-205(li)20.6(mb)-205(ar)19.7(e)-215.4(s)0(t)20.9(r)0(o)20.9(n)0(g)20.8(l)0(y)-203.9(d)0(i)20.7(s)0(c)14.1(o)0(u)20.8(r)0(a)19.7(g)0(e)19.7(d)0(.)]TJ
0 -1.1174 TD
[(Su)21(rg)15.1(er)19.7(y)-421.6(a)0(n)19.7(d)-421.6(in)20.7(va)19.7(si)20.9(ve)-412.3(pr)20.9(oc)19.7(ed)13.9(ur)20.9(es)-412.1(ar)19.7(e)-422.7(r)0(e)19.7(s)0(e)19.9(r)0(v)15.1(e)0(d)-406.5(f)0(o)15.1(r)-421.5(th)20.7(e)-422.7(m)15(os)15.3(t)]TJ
0 -1.1116 TD
[(se)19.9(ve)19.7(re)-199.2(ca)18.5(se)19.9(s,)-194.4(an)19.7(d)-202.7(e)0(v)19.7(e)0(n)-193.4(t)0(h)20.7(e)0(n)19.7(,)-205(re)19.7(su)21(lt)20.6(s)-202.5(a)0(r)14(e)-203.8(no)20.8(t)-202.8(m)0(a)18.4(i)0(n)20.7(t)0(a)19.6(i)0(n)20.7(e)0(d)-193.4(w)0(i)19.8(t)0(h)15(o)0(u)20.8(t)]TJ
T*
[(on)20.8(go)20.8(in)15(g)-266(h)0(o)15.1(m)15(e)-273(c)0(a)18.5(r)0(e)-262.5(a)0(n)19.7(d)-271.8(co)19.7(mp)19.6(re)19.7(ss)15.5(io)20.7(n.)]TJ
1.0137 -1.1174 TD
[(Pneumatic)-320(compression)-320.7(devices)-316.4(\(PCDs\))-319.1(are)-316.6(a)-313.3(convenient)]TJ
-1.0137 -1.1116 TD
[(se)19.9(l)16.1(f)0(-)20.9(m)0(a)24.2(n)0(a)19.7(g)16.2(em)18.5(e)15(n)0(t)-163.6(o)0(p)26.6(t)0(i)20.6(o)0(n)-157.7(f)0(o)20.9(r)-173.9(in)26.5(di)20.7(vi)26.5(du)20.8(a)15(l)0(s)-163.4(w)0(i)19.8(t)16.1(h)-173.9(l)0(y)20.7(m)15(ph)20.8(e)15(d)0(e)19.7(m)15(a.)]TJ
7.3823 0 0 6.5614 284.9385 521.2912 Tm
[(20)24.7(,)19.6(2)16.2(1)]TJ
9.843 0 0 9.843 62.022 505.9841 Tm
[(Advanced)-433.6(PCDs)-437.9(have)-432.9(been)-432.9(shown)-432.4(to)-428.5(stimulate)-434.2(lymphatic)]TJ
0 -1.1174 TD
[(function)-534.3(and)-528.6(improve)-534.3(patient)-534.6(limb)-530(volume,)-536.7(self-reported)]TJ
0 -1.1116 TD
[(symptoms)-535.2(and)-534.4(quality)-539.2(of)-532.1(life)-535.7(\(QoL\),)-535.1(and)-534.4(overall)-534.4(symp-)]TJ
T*
(toms.)Tj
7.3823 0 0 6.5614 83.6787 477.4676 Tm
(2225)Tj
9.843 0 0 9.843 105.8456 473.1022 Tm
[(Pump)-368.3(pressur)-8.4(e)-370.9(proles)-377.2(mimic)-372.3(the)-373.2(gentle)-377.8(stretch)]TJ
-4.4523 -1.1174 TD
[(and)-419.2(release)-427(motions)-417.9(of)-416.9(MLD,)-424.4(reducing)-420.2(risk)-419(of)-422.6(damage)-420.3(to)]TJ
0 -1.1116 TD
[(underlying)-398.3(tissue)-399.3(while)-399.5(moving)-399.6(lymphatic)-399.8(uid)-396(out)-400.9(of)-393.8(the)]TJ
T*
[(affected)-549.2(area.)-552.7(Recent)-552.7(clinical)-548.5(studies)-550.2(have)-548.1(demonstrated)]TJ
T*
[(that)-305.3(appropriate)-309.5(and)-304(regular)-309.6(use)-303.8(of)-307.4(advanced)-307.2(PCDs)-305.5(can)-305.1(sig-)]TJ
0 -1.1174 TD
[(nicantly)-409.9(improve)-413.4(the)-407.8(clinical)-410.2(outcome,)-412.3(including)-408.9(volume)]TJ
0 -1.1116 TD
[(maintenance,)-310.8(reduced)-304.9(hospitalization,)-312(and)-304(reduced)-304.9(cellulitis)]TJ
T*
[(an)19.7(d)-202.7(i)0(n)20.7(f)0(e)25.5(c)0(t)19.5(i)0(o)26.5(n)0(.)]TJ
7.3823 0 0 6.5614 114.5197 400.7621 Tm
[(21)24.7(,)19.6(2)16.2(4,)28.1(2)16.2(6)16.2()0(2)24.7(8)]TJ
9.843 0 0 9.843 152.3905 396.3968 Tm
[(Th)25.4(es)19.9(e)-209.6(c)15(li)20.6(ni)26.5(ca)18.5(l)-208.6(i)16.1(mp)19.6(ro)26.6(ve)19.7(m)15(e)0(n)19.7(t)0(s)-198(h)16.2(av)19.7(e)-203.8(a)0(l)19.5(s)0(o)]TJ
-9.181 -1.1174 TD
[(re)19.7(s)16.4(u)0(l)20.7(t)0(e)25.3(d)-323.6(in)-313.4(re)25.5(du)20.8(ce)24.3(d)-323.6(m)0(e)24.2(d)0(i)20.7(c)0(a)24.3(l)-323.8(co)19.7(s)16.4(t)0(s)20.9(.)]TJ
7.3823 0 0 6.5614 195.4204 389.7637 Tm
-.0162 Tc
[(21)-16.2(,)11.9(2)0(8)]TJ
9.843 0 0 9.843 214.8094 385.3983 Tm
0 Tc
[(A)15.3(d)0(v)20.8(a)0(n)25.4(c)0(e)18.5(d)-317.9(PC)20(Ds)-313.9(h)16.2(a)0(v)19.7(e)]TJ
-15.5224 -1.1116 TD
[(si)20.9(g)16.2(n)0(i)20.7()0(c)25.6(a)0(n)19.7(t)-185.5(di)20.7(sa)25.6(dv)20.8(an)25.4(ta)19.6(ge)25.4(s)-191(s)0(i)20.9(n)16.2(ce)-177.3(th)20.7(ey)-176.2(ar)19.7(e)-186.6(l)0(o)20.7(u)16.2(d,)-177.3(bu)20.8(lk)26.5(y,)-177.3(di)20.7(f)26.8(cu)19.7(l)16.1(t)-191.3(to)]TJ
T*
[(us)21(e)15(,)-337.5(an)19.7(d)-335.2(m)0(u)19.6(s)0(t)-324.7(b)0(e)-325.9(p)0(l)20.7(u)0(g)26.6(g)0(e)19.7(d)-335.2(in)20.7(to)-324.9(a)-342.1(w)15.3(al)19.5(l)-335.3(s)0(o)21(c)0(k)25.4(e)0(t)-331.8(t)16.1(o)-340.9(o)0(p)26.6(e)0(r)19.7(a)0(t)25.3(e)0(.)-328.2(A)0(d)20(-)]TJ
0 -1.1174 TD
[(va)19.7(n)16.2(c)0(e)18.5(d)-283.3(PC)20(D)-284.2(t)0(h)20.7(e)0(r)25.5(a)0(p)19.7(y)-283.3(al)19.5(so)-272.7(re)19.7(q)16.2(u)0(i)20.7(r)0(e)25.5(s)-288.9(th)20.7(e)-284.5(p)0(a)19.7(t)16.1(ie)19.6(nt)-273(to)-278.8(b)16.2(e)-290.2(im)25.2(mo)19.6(b)16.2(i)0(l)20.6(e)]TJ
0 -1.1116 TD
[(fo)20.9(r)-300.6(t)0(h)26.5(e)-307.5(e)15(n)0(t)20.7(i)0(r)20.7(e)-301.8(du)26.6(ra)19.7(ti)26.3(on)-290.2(of)-290.2(tr)20.7(ea)24.3(tm)19.5(e)15(n)0(t)20.7(,)-302.9(wh)25.7(ic)19.6(h)-300.6(c)0(o)25.4(n)0(s)21(e)0(q)25.4(u)0(e)19.7(n)0(t)26.5(l)0(y)-290.3(m)0(a)18.4(y)]TJ
T*
[(be)-314.4(a)-319(d)0(e)19.7(t)0(e)25.3(r)0(r)20.9(e)0(n)25.4(t)-323.8(to)-313.4(th)26.5(er)19.7(ap)25.4(y)-323.6(a)0(d)19.7(h)16.2(er)19.7(en)25.4(ce)18.5()15.1(a)0(n)-314.4(e)0(s)19.9(s)16.4(en)19.7(ti)26.3(al)-314.5(el)25.3(em)18.4(e)15(n)0(t)-313.4(t)0(o)]TJ
T*
[(im)25.2(pr)20.9(ov)26.6(e)-273(l)0(i)26.3(m)0(b)-256.9(v)0(o)20.8(l)16.1(um)19.6(e)-267.2(a)0(n)19.7(d)-266(m)15(a)0(n)19.7(a)0(g)25.4(e)-273(l)16.1(y)0(m)19.6(p)0(h)26.6(e)0(d)19.7(e)15(ma)-258(sy)21(m)15(p)0(t)20.7(o)0(m)25.4(s)0(.)]TJ
7.3823 0 0 6.5614 292.9889 324.0566 Tm
(29)Tj
9.843 0 0 9.843 72 308.6928 Tm
[(With)-266.1(the)-263.8(signicant)-266.8(burden)-266.9(of)-261.4(disease)-270.1(and)-263.7(symptom)-263.5(man-)]TJ
-1.0137 -1.1116 TD
[(agement,)-304(lymphedema)-305.1(is)-301.6(also)-299.2(associated)-303.5(with)-305(compromised)]TJ
T*
(QoL.)Tj
7.3823 0 0 6.5614 82.5448 291.1747 Tm
(30,31)Tj
9.843 0 0 9.843 102.5574 286.8094 Tm
[(Physical)-350.9(symptoms)-345.1(include)-344.4(pain,)-349(fatigue,)-347.8(decrea-)]TJ
-4.1182 -1.1174 TD
[(sed)-401.7(levels)-406.4(of)-399.6(activity,)-401(impaired)-404.3(range)-405.2(of)-399.6(motion,)-397.4(and)-401.9(hea-)]TJ
0 -1.1116 TD
[(viness)-508.6(or)-509(numbness)-506.2(in)-509.2(the)-505.7(affected)-514.6(limb.)]TJ
7.3823 0 0 6.5614 236.4094 269.2346 Tm
(3134)Tj
9.843 0 0 9.843 259.8802 264.8692 Tm
(Emotional)Tj
-20.1014 -1.1116 TD
[(symptoms)-310.5(may)-316.7(include)-309.8(changes)-316.3(in)-307.6(role)-316.7(perception,)-311.9(distress,)]TJ
0 -1.1174 TD
[(decreased)-424.4(self-condence,)-421.8(decreased)-418.7(body)-419.1(image,)-415.8(anxie)-8(ty,)]TJ
0 -1.1116 TD
[(depression,)-241.1(anger,)-241.6(and)-234.9(grief.)]TJ
7.3823 0 0 6.5614 173.4236 236.3527 Tm
(31,33,35)Tj
9.843 0 0 9.843 201.5999 231.9873 Tm
[(Decreased)-246.8(physical)-235.8(func-)]TJ
-14.1804 -1.1116 TD
[(tion,)-365.2(lack)-364(of)-365(information,)-369.6(comorbidities,)-367.2(and)-367.3(psychological)]TJ
0 -1.1174 TD
[(and)-430.7(psychosocial)-431.3(factors)-430.4(have)-432.9(all)-430.9(been)-427.2(documented)-436.3(barri-)]TJ
0 -1.1116 TD
[(ers)-309.5(to)-313.3(self-management)-318.6(of)-307.4(lymphedema)]TJ
7.3823 0 0 6.5614 220.7621 203.4708 Tm
(3638)Tj
9.843 0 0 9.843 242.3055 199.1054 Tm
[(and)-309.7(may)-316.7(exac-)]TJ
-18.3159 -1.1116 TD
[(erbate)-620.7(problems)-621.6(with)-616.1(work/life)-622.8(and)-615(ability)-619.9(to)-618.6(maintain)]TJ
T*
(employment.)Tj
7.3823 0 0 6.5614 113.896 181.5874 Tm
(39)Tj
9.843 0 0 9.843 72 166.2236 Tm
[(Reducing)-530.7(barriers)-535.1(to)-532.2(self-management)-537.4(of)-532.1(lymphedema)]TJ
-1.0137 -1.1116 TD
[(symptoms)-408.4(and)-413.4(easing)-412(life)-409(impact)-413.6(is)-405.3(essential)-416.6(to)-405.5(achieving)]TJ
T*
[(desired)-326.7(clinical)-323.8(outcomes)-323.3(and)-321.2(reducing)-322.3(the)-327.1(negative)-323.6(impact)]TJ
0 -1.1174 TD
[(on)-221.1(QoL.)-216.2(Opportunities)-224(remain)-223.4(for)-216.3(improving)-218.7(home)-219.9(treatment)]TJ
0 -1.1116 TD
[(options)-284.2(and)-280.9(adherence)-286.4(to)-278.8(benecial)-285.4(therapies.)]TJ
1.0137 -1.1116 TD
[(An)-296.8(open-label)-302.7(study)-299.2(to)-296.1(clinically)-303.1(assess)-301.9(a)-296(novel)-300.5(wearable)]TJ
-1.0137 -1.1174 TD
[(advanced)-232.3(compression)-234.3(technology)-232.5(\(Dayspring)]TJ
/F5 1 Tf
18.5002 0 TD
()Tj
/F4 1 Tf
.887 0 TD
[(,)-228.1(Fig.)-231.3(1\))-226.8(was)]TJ
-19.3872 -1.1116 TD
[(undertaken)-268(to)-267.3(determine)-274(if)-261.5(potential)-271.9(barriers)-270.2(to)-267.3(lymphedema)]TJ
T*
[(self-care)-198.7(were)-197.6(effectively)-201.4(addressed.)-200.7(The)-195.7(Dayspring)-196.2(device)-200.3(is)]TJ
0 -1.1174 TD
[(a)-336.3(novel)-340.9(FDA-cleared)-341(wearable)-342.7(sequential)-343(compression)-337.9(sys-)]TJ
0 -1.1116 TD
[(tem.)-280(The)-282.1(following)-281.9(endpoints)-287.6(were)-278.3(examined:)]TJ
26.5062 26.4774 TD
[(\(1\))-504.3(Im)19.6(pr)20.9(ov)20.8(em)18.5(en)19.7(t)-254.7(i)0(n)-244.2(Q)0(o)20(L)-255.7(in)-244.2(su)21(bj)20.7(ec)18.5(ts)-244(wi)19.8(th)-244.2(un)20.8(il)20.6(at)13.8(er)19.7(al)-245.4(up)20.8(pe)19.7(r-)]TJ
1.6703 -1.1116 TD
[(ex)19.7(tr)20.7(em)18.5(it)20.6(y)-484.9(e)0(d)19.7(e)0(m)18.5(a)-486.1(af)19.7(te)19.5(r)-484.9(2)0(8)-474.5(d)0(a)19.7(y)0(s)-474.3(a)0(s)-475.5(m)0(e)18.4(a)0(s)19.9(u)0(r)20.9(e)0(d)-475.7(b)0(y)-474.5(t)0(h)20.7(e)]TJ
0 -1.1174 TD
[(Ly)19.6(mp)19.6(he)19.7(de)19.7(ma)-586.3(Qu)20(al)13.8(it)20.6(y-)20.9(of)20.9(-L)19.7(if)15(e)-595.5(Q)0(u)20(e)0(s)14.1(t)0(i)20.6(o)0(n)20.8(n)0(a)19.7(i)0(r)20.7(e)-601.3(\(L)19.7(YM)19.1(-)]TJ
0 -1.1116 TD
[(QO)19.1(L\))-314.4(di)20.7(se)19.9(as)19.9(e-)14(sp)21(ec)18.5(i)20.9(c)-324.8(v)0(a)19.7(l)0(i)20.6(d)0(a)13.9(t)0(e)19.5(d)-323.6(as)19.9(se)19.9(ss)21.2(me)18.4(nt)-319.1(to)20.7(ol)20.7(.)]TJ
-1.6703 -1.1116 TD
[(\(2\))-504.3(Arm)-443.1(volume)-446.9(maintenance)-451.4(or)-439.9(improvement)-449.1(as)-446.7(mea-)]TJ
1.6703 -1.1174 TD
[(sured)-334.7(before)-331.4(and)-338.5(after)-336.2(28)-330.5(days)-339.4(of)-330.5(device)-338.5(use.)]TJ
-1.6703 -1.1116 TD
[(\(3\))-504.3(Safety)-331.4(as)-337.2(assessed)-339.8(by)-330.5(reported)-339.5(adverse)-333.5(events)]TJ
ET
313.058 219.288 239.131 .22676 re
f
313.058 77.442 239.131 .22678 re
f
BT
/F8 1 Tf
9.845 0 0 9.845 380.8629 224.9574 Tm
(Table)Tj
/F4 1 Tf
3.0002 0 TD
(1.)Tj
/F8 1 Tf
1.2496 0 TD
(Demographics)Tj
/F4 1 Tf
-11.137 -1.5894 TD
[(Patients)-18673.9(40)]TJ
0 -1.0135 TD
[(Age)-339(\(mean)]TJ
/F5 1 Tf
4.6817 0 TD
()Tj
/F4 1 Tf
.7141 0 TD
[(SD\))-13403.7(65.7)]TJ
/F5 1 Tf
16.9244 0 TD
()Tj
/F4 1 Tf
.7198 0 TD
(8.8)Tj
-23.0399 -1.0135 TD
[(Female)-338.9(\(male\))-15183.4(39)-330.2(\(1\))]TJ
0 -1.0077 TD
(Race)Tj
1.002 -1.0135 TD
[(Caucasian)-16725.9(32)]TJ
T*
[(African)-338.5(American)-13995.3(1)]TJ
T*
[(Hispanic)-17787.9(3)]TJ
0 -1.0077 TD
[(Other)-19067.9(4)]TJ
-1.002 -1.3187 TD
[(Affected)-340.7(arm)]TJ
1.002 -1.0077 TD
[(Left)-19170.9(22)]TJ
0 -1.0135 TD
[(Right)-18617.9(18)]TJ
-1.002 -1.3187 TD
[(Sites)-20402.9(2)]TJ
0 -1.0077 TD
[(Months)-335(since)-335.5(ALDN/RT)-10792.9(26)]TJ
/F5 1 Tf
22.0725 0 TD
()Tj
/F4 1 Tf
.7198 0 TD
(23)Tj
8.7511 0 0 8.7511 321.0519 65.6504 Tm
[(ALDN/RT,)-623.1(axillary)-616.2(lymph)-618.9(node)-618.4(dissection/radiotherapy;)-617.3(SD,)]TJ
-.9135 -1.0236 TD
[(standard)-338.6(deviation.)]TJ
ET
q
1 i
360.624 732.245 m
504.68 732.245 l
504.68 375.023 l
360.624 375.023 l
W n
q
144.057 0 0 357.222 360.624 375.024 cm
/Im1 Do
Q
Q
BT
/F7 1 Tf
9.845 0 0 9.845 313.0582 358.2424 Tm
[(FIG.)-469.2(1.)]TJ
/F4 1 Tf
4.2498 0 TD
[(Schematic)-469.9(of)-462.7(the)-465(Dayspringa)-470(smart)-468(wearable)]TJ
-4.2498 -1.0135 TD
[(deviceshown)-639.1(with)-632.8(the)-632(controller)-634.7(\()]TJ
/F6 1 Tf
16.0088 0 TD
(right)Tj
/F4 1 Tf
1.9464 0 TD
[(\))-628.7(and)-631.8(garment)]TJ
-17.9551 -1.0135 TD
(\()Tj
/F6 1 Tf
.334 0 TD
(left)Tj
/F4 1 Tf
1.2957 0 TD
(\).)Tj
/F3 1 Tf
8.9663 0 0 8.9663 62.022 749.6502 Tm
(2)Tj
45.9992 0 TD
[(ROCKSON)-337.7(ET)-338.7(AL.)]TJ
ET
endstream
endobj
32 0 obj
<>stream
Adobe d C
,
s !1AQa"q2B#R3b$r%C4Scs5D'6Tdt&
EFVU(eufv7GWgw8HXhx)9IYiy*:JZjz ? 3O7UPX#wPR*h+M'֥\:'m Yz8焔1&YcO< ΘiSs|6+? Io5֠uѯhPewqUWkU~p.HӍ?| _
_@ R9 U~oab w/ 9Yz~X 4b5~_ʯ"@}; E_NoE~ CWR?TOӘ Uo
x ww tH~ Ӓ+SɐZ4W1Uӕ:g=V-_EbF+x7%Y8SM9`ٳf͛6lٳf͛6l]OG懜 Iq=ȍҲ1ThM@TE bSPZDbhH#)JoriRZv#:~kOV}pXAГ~"V C[3Od4WP̜TOv"iw!gnSChHNƇqj-hj e;z|[( Hecs #-^~kO/B(Ҡe ?S滚
J`ONǜas`;[j2F#ni%x_%I-tFsV9S L`_.1PJ
P)Z|Goվ3/>}($G6<~:1Z"&2ay>ηn|)C
ƕJȷ6aaaJ{}$>.RI> G!lZZDax! eZ.l6lٳf͛6lٳf͛<+VI